Denali Therapeutics Inc. (MUN:4DN)

Germany flag Germany · Delayed Price · Currency is EUR
17.21
0.00 (0.00%)
At close: Dec 4, 2025
-29.17%
Market Cap 2.52B
Revenue (ttm) n/a
Net Income (ttm) -425.08M
Shares Out n/a
EPS (ttm) -2.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 94
Average Volume 155
Open 16.10
Previous Close n/a
Day's Range 16.10 - 17.21
52-Week Range 10.92 - 20.31
Beta n/a
RSI 58.05
Earnings Date Feb 27, 2026

About Denali Therapeutics

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme r... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2013
Employees 422
Stock Exchange Munich Stock Exchange
Ticker Symbol 4DN
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.